CANDEL THERAPEUTICS, INC. Increase (Decrease) in Contract with Customer, Liability
CANDEL THERAPEUTICS, INC. (CADL) reported Increase (Decrease) in Contract with Customer, Liability of -$44.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-13
- CANDEL THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$22.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$22.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-09-30 was $0.00.
- CANDEL THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2024-06-30 was $0.00.
- CANDEL THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was $178.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$192.00K, a 386.57% decline from fiscal 2022.
- CANDEL THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was $67.00K.
- CANDEL THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2021 was -$125.00K.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$22.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$44.00K 10-Q · filed 2026-08-13 | ||
| 2026-03-31 | -$22.00K 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $178.00K 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | -$156.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | -$156.00K derived: sum of 3 quarters · filed 2025-03-13 | -$168.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-14 | -$156.00K derived: sum of 2 quarters · filed 2025-03-13 | -$168.00K derived: sum of 3 quarters · filed 2025-03-13 | -$180.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-12-31 | -$156.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$168.00K derived: sum of 2 quarters · filed 2025-03-13 | -$180.00K derived: sum of 3 quarters · filed 2025-03-13 | -$192.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$24.00K derived: sum of 2 quarters · filed 2024-11-14 | -$36.00K 10-Q · filed 2024-11-14 | $125.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$24.00K 10-Q · filed 2024-08-13 | $137.00K derived: sum of 3 quarters · filed 2024-08-13 | $106.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$12.00K 10-Q · filed 2024-05-14 | $149.00K derived: sum of 2 quarters · filed 2024-05-14 | $118.00K derived: sum of 3 quarters · filed 2024-05-14 | $86.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $161.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $130.00K derived: sum of 2 quarters · filed 2024-03-28 | $98.00K derived: sum of 3 quarters · filed 2024-03-28 | $67.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | -$31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$63.00K derived: sum of 2 quarters · filed 2023-11-09 | -$94.00K 10-Q · filed 2023-11-09 | -$125.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$63.00K 10-Q · filed 2023-08-10 | -$94.00K derived: sum of 3 quarters · filed 2023-08-10 | -$125.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$31.00K 10-Q · filed 2023-05-11 | -$62.00K derived: sum of 2 quarters · filed 2023-05-11 | -$93.00K derived: sum of 3 quarters · filed 2023-05-11 | -$125.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$62.00K derived: sum of 2 quarters · filed 2023-03-30 | -$94.00K derived: sum of 3 quarters · filed 2023-03-30 | -$125.00K 10-K · filed 2023-03-30 |
| 2021-09-30 | -$31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$63.00K derived: sum of 2 quarters · filed 2022-11-10 | -$94.00K 10-Q · filed 2022-11-10 | -$125.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$63.00K 10-Q · filed 2022-08-05 | -$94.00K derived: sum of 3 quarters · filed 2022-08-05 | -$125.00K derived: sum of 4 quarters · filed 2022-08-05 |
| 2021-03-31 | -$31.00K 10-Q · filed 2022-05-12 | -$62.00K derived: sum of 2 quarters · filed 2022-05-12 | -$93.00K derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | -$31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$62.00K derived: sum of 2 quarters · filed 2022-03-29 | -$125.00K 10-K · filed 2022-03-29 | |
| 2020-09-30 | -$31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$94.00K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | -$63.00K 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |